A Review of Coagulopathy Disorders in COVID-19
Author(s): Aditi Garg, Vasant Wagh, Aditya Dhonde* and Swarupa Chakole
Abstract
Countries all over the world have been affected by Coronavirus disease which started in small city of China as epidemic but soon was declared pandemic. In this review we outline major coagulopathy which is associated with COVID-19 and its clinical implication with what should be done in future. COVID-19 has resulted in huge mortality in the population of every country irrespective of developmental status. COVID-19 related coagulopathy has significant influence in patient’s recovery. Surprisingly, this problem has been seen to occur despite prophylactic anticoagulant medication. According to recent findings, the most seriously unwell patients have coagulopathy and significant intravascular clot formation similar to Disseminated Intravascular Coagulation (DIC). Coagulation testing may so be considered. The clinical appearance of COVID-19 is important in distinguishing severe patients. Organ dysfunction is the primary effect of COVID-19 associated coagulopathy, whereas hemorrhagic event is less occurring. Massive increase of D-dimer and fibrin/FDP shows presence of coagulopathy. If we compare sepsis associated coagulopathy with COVID-19 coagulopathy disseminated intravascular coagulopathy, PT elevated are found in the latter. Antithrombin activity decreases and partial thromboplastin time is less common. COVID-19 has a low incidence of thrombocytopenia. However, the causes of coagulopathy are still unknown. It's thought that the deregulated immune system is to blame. Inflammatory cytokines coordinate immunological responses, lymphocyte cell death and endothelial injury and hypoxia are both involved.